Regulators in Europe have given Galderma's Mirvaso the green light as a treatment for facial redness.

Specifically, the European Commission has granted marketing authorisation in Europe for Mirvaso (brimonidine) which directly targets the facial erythema (redness) of rosacea. The approval is based on data collected from 553 patients enrolled in two Phase III trials of one-month duration.

Alison Layton, consultant dermatologist at Harrogate and District NHS Foundation Trust in the UK, noted that until now there has been no clinically approved treatment targeting the facial erythema of rosacea and "Mirvaso can play a key role in the treatment of facial redness". She added that the once-daily gel, an alpha-2 adrenergic receptor agonist, offers an easy-to-apply, long-acting treatment with visible reductions in facial redness within 30 minutes of application, "potentially giving them a better quality of life."

Mirvaso was approved in the USA last year and Galderma chief executive Humberto Antunes noted last month that since its launch across the Atlantic in September, "we have seen widespread adoption by dermatologists, underscoring the important need for an effective topical prescription treatment for this most common symptom of rosacea.”